A Multi-Center Open-Label Phase I/2 Study of BGB324 in Combination With Erlotinib in Patients With Stage IIIb or Stage IV Non-Small Cell Lung Cancer

Trial Profile

A Multi-Center Open-Label Phase I/2 Study of BGB324 in Combination With Erlotinib in Patients With Stage IIIb or Stage IV Non-Small Cell Lung Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 18 Oct 2017

At a glance

  • Drugs BGB 324 (Primary) ; Erlotinib
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Sponsors BerGenBio
  • Most Recent Events

    • 18 Oct 2017 Results presented at the 18th World Conference on Lung Cancer
    • 18 Aug 2017 According to a BerGenBio ASA media release, the company has completed IPO and the funds from the recent IPO will enable the company to complete the four ongoing phase II trials (NCT02488408, NCT02424617, NCT03184558, NCT03184571) including this trial with read-outs expected in the second half of 2018.
    • 17 Mar 2017 Planned End Date changed from 1 Dec 2016 to 1 Jul 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top